This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zabaleta, M Articles by Bianco, N E Search for Related Content PubMed PubMed Citation Articles by Zabaleta, M Articles by Bianco, N E Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB L-TYROSINE NITRIC OXIDE Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Activity profile in multiple sclerosis: an integrative approach A preliminary report

Institute of Immunology, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela, inmuno{at}cantv.net

R Marino

Institute of Immunology, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

J Borges

Neurology Departments of Luis Razetti, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

B Camargo

Neurology Departments of Luis Razetti, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

P Ordaz

José María Vargas Schools of Medicine, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

J B De Sanctis

Institute of Immunology, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

N E Bianco

Institute of Immunology, Central University Faculty of Medicine, Apartado 50109, Caracas 1050-A, Venezuela

In order to define an activity profile in patients with multiple sclerosis (MS), T-cell subpopulations and proliferative responses to myelin basic protein (MBP) associated with anti-MBP antibodies, nitrotyrosine levels in serum and cerebrospinal fluid (CSF), and serum CD40L (sCD154) were simultaneously assessed in 29 consecutive and untreated MS patients. When compared to controls, patients in secondary progressive stable (SP/I), or in full remission (RR/I) stages, individuals with secondary progressive active disease (SP/A) or in acute relapse (RR/A) showed a significant decrease of CD4/CD45RA⁺ T cells associated with an increase of absolute numbers of CD4/45R0⁺ T cells (p<0.001). In addition, in vitro-specific T-cell proliferative responses against MBP (SP/A, RR/A, SP/I: p<0.001 versus controls) in association with augmented sCD154 serum levels (SP/A, RR/A, versus controls p<0.001) and a significant increase of both CSF and serum levels of anti-MBP antibodies and nitrotyrosine levels (p<0.001) were also found. Thus, the simultaneous evaluation of antibody and cell-mediated immunopathological parameters, along with the effector mediators of inflammation such as the nitric oxide products, offers a new integrative approach to characterize markers of clinical activity in MS patients, which may be used at the moment of the initial diagnosis and during an apparent recurrences of the disease to monitor therapeutic protocols and to determine whether immune-based nerve destruction mechanisms are still operating in patients with few clinical findings.

Key Words: cerebrospinal fluid • multiple sclerosis • myelin basic protein • nitric oxide • sCD40L

Multiple Sclerosis, Vol. 8, No. 4, 343-349 (2002)
DOI: 10.1191/1352458502ms803oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?